E uiga i le kanesa / togafitiga / faʻataʻitaʻi-faʻafitauli / maʻi / soft-tissue-sarcoma / togafitiga

Togafitiga Togafitiga Faʻafomai mo Soft Tissue Sarcoma

Togafitiga faʻafomaʻi o suʻesuʻega suʻesuʻega e aʻafia ai tagata. O faʻataʻitaʻiga faʻafomaʻi i luga o lenei lisi e mo togafiti vaivai e faʻaaoga i le sarcoma. O faʻataʻitaʻiga uma i luga o le lisi e lagolagoina e le NCI.

O faʻamatalaga taua a le NCI e uiga ile faʻataʻitaʻi ile falemaʻi o loʻo faʻamatalaina ai ituaiga ma vaega o faʻataʻitaʻiga ma faʻafefea ona faʻatinoina. Togafitiga faʻafomaʻi e vaʻai i ni auala fou e puipuia ai, iloa ai, pe togafitia ai faʻamaʻi. Atonu e te manaʻo e mafaufau e uiga i le auai i le faʻataʻitaʻiina o togafitiga. Talanoa i lau fomaʻi mo se fesoasoani i le filifiliga pe o se tasi e talafeagai mo oe.

Erdafitinib i le togafitia o tagata gasegase ma le toe faʻafouina poʻo le faʻaaogaina o le tumaʻi tumaʻi, Non-Hodgkin Lymphoma, poʻo faʻamaʻi o le Histiocytic ma FGFR Mutations (A Pediatric MATCH Togafitiga faʻataʻitaʻi)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le erdafitinib e galue ai i le togafitia o tagata mamaʻi ma le tuma tuma, e le o le Hodgkin lymphoma, poʻo le faʻamaʻi o le histiocytic ua sosolo atu i isi nofoaga o le tino ma ua toe foʻi mai pe le tali atu i togafitiga ma FGFR suiga. Erdafitinib mafai taofi le tuputupu ae o sela kanesa i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 107 nofoaga

Tazemetostat i le togafitia o tagata mamaʻi ma le toe faʻafouina poʻo le faʻaaogaina o le tumaʻi tumaʻi, Non-Hodgkin Lymphoma, poʻo faʻamaʻi o le Histiocytic ma EZH2, SMARCB1, poʻo SMARCA4 Gene Mutations (A Pediatric MATCH Togafitiga Togafitiga)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le tazemetostat e galue ai i le togafitia o tagata mamaʻi ma le tuma faʻamaonia, non-hodgkin lymphoma, poʻo faʻamaʻi o le histiocytic ua salalau i isi nofoaga o le tino ma ua toe foʻi mai pe le tali atu i togafitiga ma maua EZH2, SMARCB1 , poʻo SMARCA4 gafa suia. Tazemetostat mafai ona taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 109 nofoaga

PI3K / mTOR Inhibitor LY3023414 i le togafitia o tagata gasegase ma le toe faʻafouina poʻo le faʻamalosiʻau alualu i luma tuma, Non-Hodgkin Lymphoma, poʻo Histiocytic faʻaletonu ma TSC poʻo PI3K / MTOR Mutations (A Pediatric MATCH Togafitiga Togafitiga)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le PI3K / mTOR taofi LY3023414 galue i le togafitia o tagata mamaʻi ma tuma, non-Hodgkin lymphoma, poʻo gasegase faʻaletonu ma TSC poʻo PI3K / MTOR suiga na salalau i isi nofoaga i le tino (metastatic) ma ua foi mai (toe tupu) pe le tali atu i togafitiga (refactory). PI3K / mTOR mea taofiofi LY3023414 ono taofia le tuputupu aʻe o sela kanesa i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 107 nofoaga

Palbociclib i le togafitia o tagata mamaʻi ma le toe faʻafouina poʻo le faʻaaogaina o le Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, poʻo le Histiocytic Disorder ma le Faʻaolaina o Suiga i Cell Cycle Genes (O le Pediatric MATCH Togafitiga Faʻataʻitaʻi)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le palbociclib e galue ai i le togafitia o tagata mamaʻi ma le Rb positive solid tumors, non-Hodgkin lymphoma, poʻo le histiocytic disorders ma le faʻagaeetia o suiga (mutations) i sela taʻamilosaga genes ua salalau i isi nofoaga i le tino ma ua oʻo mai. tua pe aua le tali atu i togafitiga. Palbociclib ono taofia le tuputupu aʻe o sela kanesa i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 97 nofoaga

Larotrectinib i le togafitia o tagata mamaʻi ma le toe faʻafouina poʻo le faʻaaogaina o le tumaʻi tumaʻi, Non-Hodgkin Lymphoma, poʻo faʻamaʻi o le Histiocytic ma NTRK Fusions (A Pediatric MATCH Togafitiga faʻataʻitaʻi)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei o le larotrectinib galue i le togafitia o tagata mamaʻi maʻi tuma, e le o le Hodgkin lymphoma, poʻo le faʻamaʻi o le histiocytic ma fusi a le NTRK ua salalau atu i isi nofoaga o le tino ma ua toe foʻi mai pe le tali atu i togafitiga. Larotrectinib mafai taofi le tuputupu ae o kanesa sela i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 109 nofoaga

Cabozantinib-S-Malate i le togafitia o tamaiti laiti o loʻo maua faʻasolosolo, Refractory, poʻo Sarcomas fou faʻamaonia, Wilms Tumor, poʻo isi faʻamaʻi uiga ese.

Lenei vaega II suʻesuʻega suʻesuʻega pe o le a le lelei o le cabozantinib-s-malate e galue ai i le togafitia o tagata mamaʻi ma sarcomas, Wilms tumo, poʻo isi tuma e le masani ai na toe foʻi mai, aua le tali atu i togafitiga, pe faʻatoa iloa. Cabozantinib-s-malate ono taofi le tuputupu aʻe o sela tuma e ala i le polokaina o nisi o enzymes e manaʻomia mo le tuputupu aʻe o le toto ma le tupu aʻe toto toto.

Nofoaga: 137 nofoaga

Olaparib i le togafitia o tagata mamaʻi ma le toe faʻafouina poʻo le faʻaaogaina o le tumaʻi tumaʻi, Non-Hodgkin Lymphoma, poʻo faʻamaʻi o le Histiocytic ma faʻaletonu i le DNA faʻaleagaina o genes (O le Pediatric MATCH Togafitiga Faʻataʻitaʻiga)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe o le a le lelei olaparib galue i le togafitia o tagata mamaʻi maʻi tuma, e le o le Hodgkin lymphoma, poʻo le faʻamaʻi o le histiocytic ma faaletonu i le deoxyribonucleic acid (DNA) faʻaleagaina genes ua salalau i isi nofoaga i le tino (maualuluga) ma ua foʻi mai (toe faʻafouina) pe le tali atu i togafitiga (refactory). Olaparib mafai taofi le tuputupu ae o tumo sela i le polokaina o nisi o enzymes manaomia mo sela tuputupu aʻe.

Nofoaga: 105 nofoaga

Vemurafenib i le togafitia o tagata gasegase ma le toe faʻafouina poʻo le faʻaaogaina o le tumaʻi tumaʻi, Non-Hodgkin Lymphoma, poʻo faʻamaʻi o le Histiocytic ma le BRAF V600 Mutations (O le Pediatric MATCH Togafitiga Faʻataʻitaʻiga)

Lenei vaega II Pediatric MATCH faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona lelei le vemurafenib i le togafitia o tagata mamaʻi maʻi tuma, e leʻo le Hodgkin lymphoma, poʻo faʻamaʻi o le histiocytic ma le BRAF V600 na suia i isi nofoaga o le tino ma ua toe foʻi mai pe le tali atu i togafitiga. Vemurafenib ono taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 106 nofoaga

Atezolizumab i le togafitia o tagata mamaʻi ma le fou faʻamaonia ma Metastatic Alveolar vaivai vaega Sarcoma e le mafai ona aveʻesea e taotoga.

Lenei vaega II suʻesuʻega suʻesuʻe le lelei o le atezolizumab galue i le togafitia o tagata mamaʻi ma le alveolar vaivai vaega sarcoma e leʻi togafitia, na salalau mai le mea na amata ai i isi nofoaga i le tino ma e le mafai ona aveʻesea e le taotoga. Immunotherapy ma monoclonal antibodies, pei o atezolizumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tutupu ma salalau.

Nofoaga: 39 nofoaga

Nivolumab ma Ipilimumab i le togafitia o tagata mamaʻi ma le HIV Associated Toe faʻafouina pe Refractory Classical Hodgkin Lymphoma poʻo Tumors Tumau O Na Metastatic pe Le Mafai Ona Aveʻesea e le Taʻotoga.

Lenei vaega I suʻesuʻega suesueina le itu aafiaga ma sili ona lelei tui o le nivolumab pe a tuuina atu ma ipilimumab i le togafitia o tagata mamaʻi ma le puipuia o le siama o le tagata (HIV) fesootai masani Hodgkin lymphoma na toe foi mai i le maeʻa ai o se vaitaimi o le alualu i luma pe le tali atu i togafitiga, po o tuma mautu ia ua salalau i isi nofoaga o le tino pe le mafai ona aveʻesea e ala i se taʻotoga. Immunotherapy ma monoclonal antibodies, e pei o ipilimumab ma nivolumab, ono fesoasoani i le tino o le tino puipuia osofaia le kanesa, ma ono faʻalavelave i le mafai o tumo sela e tutupu ma salalau. Ipilimumab o se vailaʻau e faʻasaga i se molemole taʻua o le cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 faʻatonutonuina se vaega o lau puipuiga i le tapunia i lalo. Nivolumab o se ituaiga o vailaʻau e faʻapitoa mo tagata faʻapolokalameina oti sela 1 (PD-1), o se polotini e nafa ma le faʻatamaʻia o sela puipuia. O le tuʻuina atu o le ipilimumab ma le nivolumab e mafai ona sili atu le lelei ile togafitia o tagata mamaʻi e maua ile HIV masani Hodgkin lymphoma poʻo le tuma faʻatusatusa i le ipilimumab ma le nivolumab naʻo ia.

Nofoaga: 28 nofoaga

MDM2 Inhibitor AMG-232 ma Radiation Therapy i le togafitia o tagata mamaʻi ma le Soft Tissue Sarcoma

Lenei vaega Ib suʻesuʻega suʻesuʻeina le itu aʻafiaga o MDM2 inhibitor AMG-232 ma radiation togafitiga i le togafitia o tagata mamaʻi ma le vaivai sela sarcoma. MDM2 taofi AMG-232 ono taofi le tuputupu ae o kanesa sela i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe. O le tuʻuina atu ole MDM2 mea e taofia ai le AMG-232 ma le faʻamālōlōina muamua aʻo leʻi faia se taotoga e ono faʻaititia ai le tuma ma faʻaititia ai le aofaʻi o mea masani e tatau ona aveʻesea

Nofoaga: 27 nofoaga

Nivolumab ma poʻo aunoa Ipilimumab i le togafitia Tamaiti Maʻi ma Faʻasolosolo poʻo Refractory Maʻa Tumors poʻo Sarcomas

Lenei vaega I / II suʻesuʻega suʻesuʻeina le itu aʻafiaga ma sili ona lelei fualaʻau o le nivolumab pe a tuʻuina atu i ai pe leai ipilimumab e vaʻaia pe o le a le lelei latou te galue ai i le togafitia o tamaiti gasegase maʻi puta poʻo ni sulu na toe foʻi mai (toe tupu) pe le tali atu i togafitiga ( faʻaola). Immunotherapy ma monoclonal antibodies, pei o le nivolumab ma ipilimumab, e ono fesoasoani i le tino o le tino i osofaʻiga o le kanesa, ma ono faʻalavelave ai ile mafai o sela tuma e tutupu ma sosolo. E leʻo iloa pe o nivolumab e sili atu lona galue naʻo ia poʻo le ipilimumab i le togafitia o tagata mamaʻi ua iai faʻafuaseʻi ni paʻu poʻo ni sisika.

Nofoaga: 24 nofoaga

Selinexor i Advanced Liposarcoma

Lenei o se randomized, multicenter, lua-tauaso, placebo-pulea, Vaega 2-3 suʻesuʻega o tagata mamaʻi ua maua i le alualu i luma le teuteuina liposarcoma. E tusa e 279 le aofaʻi o tagata mamaʻi o le a faʻasolosolo e suʻesuʻe togafitiga (selinexor poʻo le placebo).

Nofoaga: 21 nofoaga

(VOYAGER) Suʻesuʻega o Avapritinib vs Regorafenib i Tagata Maʻi O loʻo maua i le lotoifale maualuluga le toe faʻafouina poʻo Metastatic GIST.

Lenei o se matala-faʻailoga, randomized, Phase 3 suʻesuʻega i tagata mamaʻi i le lotoifale alualu i luma unresectable po metastatic GIST (alualu i luma GIST) o avapritinib (lauiloa foi BLU-285) faʻatusatusa regorafenib i tagata mamaʻi na togafitia ma imatinib ma 1 pe 2 isi TKI.

Nofoaga: 14 nofoaga

O le Vaega 1 Suʻesuʻega o le EZH2 Inhibitor Tazemetostat i Pediatric mataupu e faʻasolosolo ona toe faʻafouina pe faʻafouina INI1-Negative Tumors poʻo le Synovial Sarcoma

Lenei o le Vaega I, matala-igoa, fualaʻau faʻateleina ma fualaʻau faʻalauteleina suʻesuʻega ma se BID tuʻu fofoga o le tazemetostat. O mataupu o le a suʻesuʻeina mo le agavaʻa i totonu o le 14 aso o le fuafuaina muamua inumaga o le tazemetostat. Ole taamilosaga ole togafitiga ole 28 aso. Tali tali o le a iloiloina pe a maeʻa 8 vaiaso o togafitiga ma mulimuli ane uma 8 vaiaso ao faia suʻesuʻega. O le suʻesuʻega e lua ona vaega: Faʻasologa Faʻatumu ma Faʻalauteleina o Toto Faʻalaʻeiina o vailaʻau mo mataupu e iai male faʻafitauli o loʻo sosoʻo mai i lalo: - Tuma ole Rhabdoid: - Tumete ole atapeti o le rhabdoid tuma (ATRT) :

Nofoaga: 14 nofoaga

Adavosertib ma Irinotecan Hydrochloride i le togafitia o tamaiti laiti ma le toe faʻafouina poʻo Refractory mautu Tumors

Lenei vaega I / II suʻesuʻega suʻesuʻeina le itu aafiaga ma sili ona lelei fualaʻau o le adavosertib ma le irinotecan hydrochloride i le togafitia o talavou gasegase ma mautu tuma na toe foi mai (toefaʻafouina) pe na le tali atu i le masani togafitiga (refractory). Adavosertib ma irinotecan hydrochloride ono taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 22 nofoaga

O le Vaega III Faʻataʻitaʻiga o le Anlotinib i le Metastatic poʻo le Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma ma le Synovial Sarcoma

O lenei suʻesuʻega e iloilo ai le saogalemu ma le aoga o le AL3818 (anlotinib) hydrochloride i le togafitia o le metastatic poʻo le alveolar soft vaega sarcoma (ASPS), leiomyosarcoma (LMS), ma le sinovial sarcoma (SS). O i latou uma e auai ma ASPS o le a mauaina faʻailoga matala AL3818. I tagata auai ma LMS poʻo SS, AL3818 o le a faʻatusatusa i le IV dacarbazine. Lua vaetolu o tagata auai o le a mauaina AL3818, tasi-vae tolu o tagata auai o le a mauaina IV dacarbazine.

Nofoaga: 14 nofoaga

Nab-Paclitaxel ma Gemcitabine Hydrochloride i le togafitia o Talavou poʻo Talavou Matutua ma Faʻasolosolo poʻo Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, poʻo Soft Tissue Sarcoma

Lenei vaega II suʻesuʻega suʻesuʻega pe o le a le nab-paclitaxel ma le gemcitabine hydrochloride galue i le togafitia o talavou poʻo talavou matutua ma le osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, po o le malulu sela sarcoma ua toe foʻi mai pe le tali mai i togafitiga. O vailaʻau o loʻo faʻaaogaina i chemotherapy, pei o nab-paclitaxel ma gemcitabine hydrochloride, e galulue i auala eseese e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, e ala i le taofiina o latou mai le vaeluaina, poʻo le taofia o latou mai le sosolo.

Nofoaga: 18 nofoaga

Olaparib ma Temozolomide i le togafitia o tagata mamaʻi ma alualu i luma, Metastatic, poʻo Unterectable Uterine Leiomyosarcoma

Lenei vaega II suʻesuʻega suʻesuʻega olaparib ma temozolomide i le togafitia o tagata mamaʻi ma uterine leiomyosarcoma (LMS) ua salalau i isi nofoaga i le tino (alualu i luma pe metastatic) pe le mafai ona aveʻesea e le taotoga (le mafai ona faʻamalosia). Olaparib mafai taofi le tuputupu ae o tumo sela i le polokaina o nisi o enzymes manaomia mo sela tuputupu aʻe. O vailaʻau o loʻo faʻaaoga i chemotherapy, pei o temozolomide, e galue i auala eseese e taofi ai le tuputupu aʻe o sela tuma, a le o le fasiotia o sela, ala i le taofiina latou mai le vaeluaina, poʻo le taofiina latou mai le sosolo. O le foaʻi o le olaparib ma le temozolomide atonu e sili atu lona aoga nai lo le tuʻuina atu i se tasi o vailaʻau, e togafitia ai tagata mamaʻi ile LMS.

Nofoaga: 12 nofoaga

O le Saogalēmū, Faʻapalepale ma le PK Suʻesuʻega o le DCC-2618 i Tagata Maʻi E iai Maʻi Maualuluga

Lenei o le Vaega 1, matala-igoa, muamua-i totonu o le tagata (FIH) fualaʻau-faʻateleina suʻesuʻega fuafuaina e iloilo le saogalemu, faʻapalepaleina, vailaʻau (PK), vailaʻau vailaʻau (PD) ma muamua antitumor gaioiga o le DCC-2618, faʻatonutonu tuʻufofoga (PO), i tagata matutua tagata mamaʻi ma gasegase matua. O le suʻesuʻega e aofia ai vaega e 2, o le fualaʻau-faʻateleina laʻasaga ma le faʻalauteleina vaega.

Nofoaga: 12 nofoaga

Nelfinavir Mesylate i le togafitia o tagata mamaʻi ma Kaposi Sarcoma

O lenei pailate vaega II faʻataʻitaʻiga suʻesuʻega pe faʻafefea ona aoga tele le nelfinavir mesylate e togafitia ai tagata mamaʻi ma le Kaposi sarcoma. Nelfinavir mesylate mafai ona taofi le tuputupu aʻe o sela tuma i le polokaina o nisi o enzymes manaʻomia mo sela tuputupu aʻe.

Nofoaga: 11 nofoaga

sEphB4-HSA i le togafitia o tagata mamaʻi ma Kaposi Sarcoma

Lenei vaega II suʻesuʻega suʻesuʻega recombinant EphB4-HSA fusion protein (sEphB4-HSA) i le togafitia o tagata mamaʻi ma le Kaposi sarcoma. E mafai ona poloka e le recombinant EphB4-HSA fusion protein le tuputupu aʻe o ala toto e maua ai le toto i le kanesa, ma ono puipuia ai foʻi sela o le kanesa mai le tutupu.

Nofoaga: 10 nofoaga

O le Vaega II, Multicenter Suesuega o le EZH2 Inhibitor Tazemetostat i Matutua Matutua Faʻatasi ma INI1-Leaga Tumua poʻo Toe Faʻafoe / Refractory Synovial Sarcoma

Lenei o le Vaega II, multicenter, tatala-igoa, tasi lima, 2-tulaga suʻesuʻega o tazemetostat 800 mg BID faʻatonutonu tuʻuina i faʻaauau pea 28 aso taʻamilosaga. O le suʻesuʻeina o mataupu e fuafua ai le agavaʻa mo le suʻesuʻega o le a faia i totonu o le 21 aso o le muamua fuafuaina fualaʻau o le tazemetostat. O mataupu agavaʻa o le a lesitalaina i totonu o se tasi o fivecohorts faʻavae i ituaiga tuma: - Cohort 1 (Tapunia mo le lesitalaina): MRT, RTK, ATRT, poʻo filifilia tuma ma rhabdoid foliga, e aofia ai tamaʻi sela sela o le ovary hypercalcemic ituaiga [SCCOHT], faʻapena foi lauiloa o le mama rhaboid tumo o le ovary [MRTO] - Cohort 2 (Tapunia mo le lesitalaina): Toe faʻafouina poʻo le toe faʻafouina sinovial sarcoma ma SS18-SSX toe faʻafouina - Cohort 3 (Tapunia mo le lesitalaina): Isi INI1 le lelei tuma poʻo se mautu tuma ma le EZH2 mauaina o gaioiga (GOF) suiga, aofia ai:

Nofoaga: 12 nofoaga

SARC024: O Le Palanikete Protocol e Suʻesuʻe ai Tautala Tautala i Tagata Maʻi Ma Filifilia Sarcoma Subtypes

E ui lava na faʻamaonia regorafenib mo le faʻaaogaina i tagata mamaʻi na alualu i luma GIST e ui lava i le imatinib ma / po o le sunitinib i luga o le faʻavae o le vaega II ma le vaega III faʻamaumauga, e le i suʻesuʻeina i se faiga masani i tagata mamaʻi ma isi ituaiga o sarcoma. Talu ai le gaioiga o le sorafenib, sunitinib ma pazopanib i totonu o mea vaivai o le sarcomas, ma le faʻamaoniga o le gaioiga o le sorafenib i le osteogenic sarcoma ma atonu o le Ewing / Ewing-pei sarcoma, o loʻo i ai le faʻataʻitaʻiga e suʻesuʻeina SMOKI (tamaʻi mole mole mole taofiofia mea faʻapipiʻi) pei o regorafenib i sarcomas ese mai GIST. O loʻo faʻapea foi ona iloa o SMOKI (tamaʻi mole mole mole faʻapipiʻi mea faʻapipiʻi) pei o le regorafenib, sorafenib, pazopanib, ma le sunitinib o loʻo soʻosoʻo pupuni o kinase ia e taofi faʻatasi. E ui e le tutusa,

Nofoaga: 10 nofoaga

Saogalēmū, Faʻapalepale ma Fale Talavai a le Aneti-PD-1 Monoclonal Antibody i Matāʻupu E iai Mālōlōga Maualuga.

O le autu faʻamoemoega o le iloiloina o le saogalemu ma le faʻapalepaleina o Toripalimab i mataupu ma eseese tulaga le lelei faʻatamaia ma iloiloina le fautuaina Phase 2 fualaʻau. O faʻamoemoega lona lua o le: 1) faʻamatalaina le vailaʻau mo vailaʻau (PK) o le Toripalimab, 2) iloiloina gaoioiga a le antitumor o Toripalimab; 3) fuafua le puipuiga o le Toripalimab; 4) iloilo atoa le ola. O le suʻesuʻega o sini ia: 1) iloiloina biomarkers e ono fesoʻotaʻi ma gaioiga a Toripalimab, 2) iloiloina vailaʻau o le Toripalimab i luga o le faʻatutuina o latou talimalo, faʻapolokalameina sela oti 1 (PD-1), faʻapea foʻi ma aʻafiaga i le puipuiga o le tino. 3) iloilo le aoga o PD-L1 & faʻaopopo faʻailoga suʻesuʻe e avea ma biomarkers e mafai ona fesoasoani i le filifilia o mataupu talafeagai mo TAB001 togafitiga,

Nofoaga: 9 nofoaga